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Abstract  
Aim: Aim of the study was the evaluation of the effect of dual blockade of the renin-angiotensin 
system (RAS) on proteinuria.  
Material and Methods: Sixty patients, included in the study, were treated with angiotensin-
converting enzyme inhibitor and angiotensin receptor blocker for a period of 3 months.  
Results: The dual blockade of RAS resulted with decrease of proteinuria, a slight increase of 
serum creatinine and was not associated with a lowering of blood pressure. 
Conclusion: Combined therapy with ACE-I and ARB results in a more complete blockade of the 
RAS than monotherapy. In proteinuric nephropathies it reduces significantly baseline proteinuria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 The renin-angiotensin system plays a 
fundamental role in the maintenance and regulation of 
the extracellular fluid volume and blood pressure [1]. 
Angiotensin-converting enzyme (ACE) inhibitors and 
angiotensin II receptor blockers (ARB) are widely 
used in the treatment of hypertension, chronic kidney 
disease, and heart failure [2, 3]. Despite its potential 
advantages, combination therapy with an ACE 
inhibitor and an ARB is not without risks. Significant 
decline in renal function is a rare but possible adverse 
effect of this drug combination. A more frequent 
adverse effect is a slight reduction in glomerular 
filtration rate (GFR), also hyperkalemia. Acute 
compromise of renal function was observed in a child 
after coadministration of lisinopril and losartan [4].  
 Both ACE-I and ARB impede the 
progressive deterioration in renal function, which 
underscores renal injury, particularly in patients with 
diabetic nephropathy [5-7].
 
The renoprotective effects 
of these drugs, in part, relates to their ability to reduce 
proteinuria [8, 9]. It was just a matter of time before 
ACE-I and ARB were given together as combination 
therapy, due to evidence suggesting that these agents 
are complementary in their actions. The studies of 
combination therapy in proteinuric chronic kidney 
disease (CKD) have proven interesting data for their 
antiproteinuric and renoprotective efficassity [10-14].  
 The aim of the present study was the 
evaluation of the effect of dual blockade of renin-
angiotensin system on proteinuria in non-diabetic 
patients.  
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Materials and Methods  
 Sixty non-diabetic patients with glomerular 
and intersticial disease were included in a prospective 
controlled study, with primary outcome the measure of 
proteinuria. The study had been approved by the Ethic 
Committee. At baseline 24 hour proteinuria was 
measured, as well as serum creatinine (SCr) and 
GFR, measured by Cockcroft-Gault formula, seric 
sodium, potassium and blood pressure (BP); at 
baseline clinic blood pressure was 168 ± 25.8 / 81 ± 
1.1 mmHg, SCr was 1.39 ± 0.4 mg/dl, seric sodium 
141 ± 3.5 mmol/l, seric potassium 4.2 ± 0.5 mmol/l, 
and urinary proteinuria was 3.1 ± 1.5 g/day. After the 
completion of the baseline exams, an ACE-I (enalapril 
20 mg/day) or an ARB (valsartan 80 mg/day) was 
given for a period of 3 months; at the end of this 
period a repeat of all exams was done, and the 
combined treatment with ACE-I+ARB was started and 
continued for a further 3 months period, and at the 
end all the exams were repeated. All variables are 
presented as mean ± standard deviation. Differences 
were considered significant at the p<0.05 levels. We 
used paired t tests (which account for the same 
patients providing data for both treatment groups) to 
determine the effects of treatment. 
 
Results 
 From 60 patients, 25 were females and 35 
were males, with mean age 35.3 ± 4.7 (range: 35-70 
years-old) (Table 1).  
Table 1: Patients’ demographics and baseline data. 
 
Demographic variable Total number of patients 
N 60 
Sex (M/F) 35/25 
Age (years) 35.3 ± 4.7 (35-70) 
Weight (kg) 64.2 ± 6.7 (54-96) 
Height (cm) 162.7 ± 7.4 (154-189) 
 
 Monotherapy with ACE-I or ARB resulted in a 
non significant change of blood pressure, while seric 
level of potassium and sodium, Scr and GFR were not 
changed significantly. The 24 hour proteinuria 
decreased in both groups, but this was not significant. 
The combined treatment with ACE-I+ARB resulted in 
a significant reduction of proteinuria (2.1 ± 0.5 g/day 
vs. 3.1 ± 1.5 g/day at baseline, P<0.01). The renal 
function was not significantly altered (SCr increased 
not significantly to 1.5 ± 0.16 mg/dl (P=0.06), while 
seric level of potassium remained unchanged. The 
values of systolic and diastolic blood pressure were 
reduced but not significantly (Table 2).         
 
Discussion   
 This study shows that ACE-I and ARB are 
effective and well-tolerated antihypertensive agents. 
Although not all patients who are treated with ACEI or 
ARB show a clear antiproteinuric response [15], our 
data show efficacy of enalapril and valsartan as 
regard the decrease of proteinuria from the baseline 
values. The results of a limited number of studies 
support the notion that additive antihypertensive, 
cardioprotective, and antiproteinuric effects may be 
obtained when ACE-I and ARB are combined [16].  
Table 2: Comparison of clinical and biochemical 
parameters. 
 
 
 
 
Baseline 
values 
 
After 3 months of treatment 
 
 
ACE-
I+ARB 
After 6 
months of 
treatment 
 
 
p 
Group with 
ACE-I (30 
patients) 
Group with 
ARB (30 
patients) 
SBP 
(mmHg) 
164 ± 20.8 160 ± 23.7 159 ± 22.6 142 ± 13 NS 
DBP 
(mmHg) 
81 ± 10.1 79 ± 10 78 ± 9.8 76.7 ± 6.2 NS 
SCr (mg/dl) 1.39 ± 0.4 1.39 ± 0.9 1.41 ± 0.6 1.5 ± 0.16 NS 
GFR 
(ml/min) 
82 ± 9.2 80 ± 8.1 81 ± 6.9 77.3 ± 8.1 NS 
Seric level 
of sodium 
(mmol/l) 
 
141 ± 3.5 
 
142 ± 2.6 
 
141.6 ± 2.9 
 
140.8 ± 3.6 
 
NS 
Proteinuria 
(24 hour) 
(g/dl) 
 
3.1 ± 1.5 
 
2.8 ± 0.7 
 
2.7 ± 0.6 
 
2.1 ± 0.5 
 
0.001 
Seric level 
of 
potassium 
(mmol/l) 
 
4.2 ± 0.5 
 
4.3 ± 0.2 
 
4.2 ± 0.9 
 
4.3 ± 0.6 
 
NS 
SBP–systolic blood pressure; DBP–diastolic blood pressure; SCr–seric level of 
creatinine; GFR–glomerular filtration rate  
 
 In chronic proteinuric non-diabetic 
nephropathies, most studies have shown a superior 
effect of the combination of ACE-I and ARB on 
proteinuria reduction in comparison with single 
therapy with ACE-I or ARB [8]. In our study, the dual 
blockade of renin-angiotensin system resulted in a 
decrease of proteinuria, although with a slight 
increase of serum creatinine due to hemodynamic 
effects of both these drugs, but without hyperkalemia. 
In our study the values of systolic and diastolic blood 
pressure were reduced but not significantly, this 
probably for the reason of a regular sodium diet. 
Recently, Slagman et al. reported that dietary sodium 
restriction to a level recommended in guidelines was 
more effective than dual blockade for reduction of 
proteinuria and blood pressure in non-diabetic 
nephropathy [17]. However, the results of recently 
published ONTARGET study has shown that 
combination of the two drugs (ACE-I and ARB) has 
not shown benefits in renal outcomes. The decision 
whether to initiate dual RAS blockade for an individual 
patient, therefore requires careful assessment of their 
risk of renal progression [18]. 
 Our findings support the effects on 
protenuria of combined therapy with ACE-I and ARB. 
Further works would need to determine more accurate 
information of the changes in the GFR, BP under the 
influence of this applied therapy.  
 Conclusion: Combined therapy with ACE-I 
and ARB results in a more complete blockade of the 
RAS than monotherapy. In proteinuric nephropathies 
it reduces significantly baseline proteinuria.  
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